Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Shares of Opthea Limited (NASDAQ:OPT – Get Free Report) have been assigned an average recommendation of “Hold” from the six ...

Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination ...

Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other ...

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

Opthea Limited (OPT), a biopharmaceutical firm, has decided to discontinue its Phase 3 clinical program for sozinibercept in treating wet age-related macular degeneration (wet AMD). This decision ...